I-MAB (IMAB) Gross-Profit-to-Asset % : 0.52% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. I-MAB's annualized Gross Profit for the quarter that ended in Dec. 2023 was $2.24 Mil. I-MAB's average Total Assets over the quarter that ended in Dec. 2023 was $428.16 Mil. Therefore, I-MAB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.52%.

I-MAB Gross-Profit-to-Asset % Historical Data

The historical data trend for I-MAB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Gross-Profit-to-Asset % Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.44

38.79

0.71

-4.88

0.81

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								0.81	0.91	-11.80	1.02	0.52

Competitive Comparison of I-MAB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, I-MAB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where I-MAB's Gross-Profit-to-Asset % falls into.

I-MAB Gross-Profit-to-Asset % Calculation

I-MAB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	3.872	/	( (584.314	+	365.952)	/ 2 )
	=	3.872	/	475.133
	=	0.81 %

I-MAB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	2.238	/	( (490.364	+	365.952)	/ 2 )
	=	2.238	/	428.158
	=	0.52 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

I-MAB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of I-MAB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.